Payment overview · 2025
General Payments
$55.80
1 reported records · 1 companies
Healthcare provider profile · identity verified
Claudell Stephens, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PINOLE, CA · NPI 1437240850
Verified facts
What the public records show
CMS Open Payments records show Claudell Stephens, M.D. received $55.80 in general payments during 2025 across 1 reported records.
VERTEX PHARMACEUTICALS INCORPORATED accounted for 100.0% of that reported general-payment amount.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $55.80 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $55.80 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 514 | 150 |
| Amlodipine Besylate | Amlodipine Besylate | 327 | 93 |
| Metformin Hcl | Metformin Hcl | 273 | 68 |
| Lisinopril | Lisinopril | 258 | 72 |
| Levothyroxine Sodium | Levothyroxine Sodium | 230 | 45 |
| Gabapentin | Gabapentin | 210 | 56 |
| Losartan Potassium | Losartan Potassium | 182 | 46 |
| Furosemide | Furosemide | 159 | 29 |
| Jardiance | Empagliflozin | 143 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 110 | 32 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 107 | 31 |
| Simvastatin | Simvastatin | 101 | 24 |
| Famotidine | Famotidine | 97 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 93 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 83 | 24 |
| Ibuprofen | Ibuprofen | 82 | 23 |
| Trazodone Hcl | Trazodone Hcl | 81 | 19 |
| Eliquis | Apixaban | 77 | 15 |
| Alendronate Sodium | Alendronate Sodium | 76 | 25 |
| Tramadol Hcl | Tramadol Hcl | 65 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 64 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 12 |
| Omeprazole | Omeprazole | 52 | 19 |
| Naproxen | Naproxen | 51 | 16 |
| Potassium Chloride | Potassium Chloride | 51 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 22 |
| Carvedilol | Carvedilol | 47 | 14 |
| Ozempic | Semaglutide | 46 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 12 |
| Lorazepam | Lorazepam | 45 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 19 |
| Sertraline Hcl | Sertraline Hcl | 44 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 43 | 17 |
| Montelukast Sodium | Montelukast Sodium | 40 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 39 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 13 |
| Allopurinol | Allopurinol | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Mirtazapine | Mirtazapine | 35 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 14 |
| Finasteride | Finasteride | 30 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Meloxicam | Meloxicam | 28 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Mupirocin | Mupirocin | 20 | 11 |
| Humulin R | Insulin Regular, Human | 19 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Ssd | Silver Sulfadiazine | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Olanzapine Odt | Olanzapine | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Thioridazine Hcl | Thioridazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $55.80 · 1 records | VERTEX PHARMACEUTICALS INCORPORATED | — | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error